PCSSB Information and Tools

BACKGROUND

The “Drug Addiction Treatment Act of 2000” creates the long-awaited opportunity to expand treatment for opiate dependence into the mainstream of medical practice, increase the number of persons treated and have an important positive public health impact.

The legislation specifies several ways in which physicians can be considered “qualified” to prescribe and dispense buprenorphine in their offices for the treatment of opioid dependence. Some will need to complete training prior to notifying the U.S. Department of Health and Human Services (DHHS) of their intention to begin prescribing buprenorphine for the treatment of opioid dependence. Others, such as those certified in Addiction Medicine or Addiction Psychiatry or those who participated in clinical trials, are not required to complete any further training. However, it is likely that many physicians who are defined as qualified, by virtue of their subspecialty certification or specific experience, will elect to take part in an educational program to review the many elements involved in implementing this new treatment modality in a setting where pharmacological management of opioid dependence has not been provided before.

ABOUT THE TRAINING

AAAP is one of five organizations designated by the U.S. Department of Health and Human Services (DHHS) to provide such training for physicians to dispense buprenorphine in office practice for treatment of opioid dependence. AAAP Buprenorphine Training Sessions meet the eight hour requirement.

Participation in training will provide physicians with a comprehensive overview of buprenorphine prescribing and its safe and effective use in an office-based setting.

This training is designed for physicians who are likely to treat opiate-dependent persons in their practice, such as those in family practice, general internal medicine, psychiatry, pediatrics and adolescent medicine specialists.

This training would be most valuable for:

  • Physicians and other primary care providers who are not addiction specialists who would like to provide treatment for opiate-addicted patients.
  • Addiction specialists who provide treatment for opiate addiction and who want to increase treatment options.
  • Addiction specialists who have not treated opiate addiction in their practices, but who want to learn how to do so.

WHEN & WHERE

Training will be offered through national meetings, regional workshops and the Internet. Scheduled sessions and online instructions are posted on here. For more information, contact AAAP.

Buprenorphine for Nurses

Click here for the TAP 30: Buprenorphine: A Guide for Nurses

The guide is #30 in the Technical Assistance Publication (TAP) series released by SAMHSA's Knowledge Application Program (KAP). TAPs are compilations from various sources that provide practical guidance and information related to the delivery of treatment services to individuals with alcohol and drug abuse disorders, issued by SAMHSA's Center for Substance Abuse Treatment (CSAT). TAP 30 serves as a resource in improving treatment outcomes for individuals receiving office-based treatment for  opioid addiction.

TAP 30 addresses the following topics:

  • Buprenorphine and the Role of the Nurse

  • Buprenorphine Pharmacology

  • Buprenorphine Treatment Protocols-Office-Based Treatment

  • Precipitated Withdrawal and Withdrawal Symptoms

  • Physicians' and Patients' Responsibilities

  • Nursing Practice and the Use of Buprenorphine for the Treatment of Opioid Addiction